Given the limited awareness of non-radiographic axial spondyloarthritis, differentiating this disease from radiographic disease and prescribing appropriate therapy remains a key challenge, according to a presentation at the Biologic Therapies Summit. “Epidemiological knowledge in the United States about this disease is limited,” Marina Magrey, MD, the rheumatology fellowship program